Clinical trial

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

NCT05018702

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-07-14

PhasePHASE2

Study timeline

Study start (actual)2021-07-14Date precision: day

Registry last updated2022-06-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive, Metastatic Breast Cancerunresolved

Interventions

ARX788DRUG

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05018702 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.